GlassScriptPhysician profile
Jill Rau
NPI 1316474216
$59,321.51
in general payments reported to CMS, 2019-2025
13 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,496 · 2020: $93.35 · 2021: $142 · 2022: $120 · 2023: $13K · 2024: $16K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Honoraria: $2,260 · Consulting Fee: $2,183 · Food and Beverage: $1,781 · Travel and Lodging: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,012.50 |
| Honoraria | $2,260.00 |
| Consulting Fee | $2,182.50 |
| Food and Beverage | $1,780.61 |
| Travel and Lodging | $234.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $52,087.32 | 2022-2025 | |
| Lundbeck LLC | $4,231.26 | 2024-2025 | Vyepti |
| Amgen INC. | $2,116.07 | 2019 | |
| Allergan, INC. | $187.58 | 2019-2021 | |
| Averitas Pharma INC. | $180.33 | 2024-2025 | Qutenza |
| Siemens Medical Solutions USA, INC. | $159.89 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $143.73 | 2019 | |
| Biogen, INC. | $93.78 | 2021 | |
| Celgene Corporation | $54.42 | 2022 | |
| Alexion Pharmaceuticals, INC. | $31.55 | 2021-2022 | |
| Tanabe Pharma America, INC. | $18.24 | 2021 | |
| Lilly USA, LLC | $17.34 | 2023 | Emgality, Reyvow |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Rau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.